Plain-English translation of NCT07610538 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether aldesleukin, a medication that boosts immune cells called regulatory T cells, can help your heart heal better after bypass surgery. Right now, researchers know this medication works on immune cells in the bloodstream, but they want to understand if it can also work on immune cells in heart tissue itself, where healing happens. If it works, this could potentially reduce the risk of developing heart failure after your surgery.
Heart bypass surgery saves lives, but it causes significant damage to heart tissue that can lead to heart failure down the road. This trial is exploring whether this medication can help your body repair that damage more effectively by activating special immune cells in your heart tissue that promote healing and reduce inflammation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be randomly assigned to receive either the new medication at one of two doses or standard care alone following your bypass surgery. The medication would be given by injection on specific days as determined by the research team. You would attend follow-up visits so researchers can monitor how well your heart is healing and check for any side effects. The study is designed to be relatively small with only 24 participants total, and most of the focus will be on understanding what happens to immune cells in your heart tissue during the healing process.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United Kingdom